Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL28524248 | 0.91 | POLB (0.43) | POLBCA1CA2CA7CA14 | |
| SCHEMBL12195208 | 0.87 | CA5B (0.48) | POLBCA1CA2CA7CA14 | |
| SCHEMBL9355619 | 0.86 | POLB (0.50) | POLBCA2CA7CA14ALDH1A1 | |
| SCHEMBL11957576 | 0.85 | ALDH1A1 (0.37) | POLBCA2CA7CA14ALDH1A1 | |
| SCHEMBL16589750 | 0.85 | PAOX (0.35) | POLBCA1CA2CA7CA14 | |
| SCHEMBL10431428 | 0.84 | PAOX (0.57) | POLBCA2CA7CA14ALDH1A1 | |
| SCHEMBL16316312 | 0.84 | POLB (0.50) | POLBCA1CA2CA7CA14 | |
| SCHEMBL6692722 | 0.83 | ALDH1A1 (0.36) | POLBCA2CA7CA14ALDH1A1 | |
| SCHEMBL9501632 | 0.83 | ALDH1A1 (0.36) | POLBCA2CA7CA14ALDH1A1 | |
| SCHEMBL23244769 | 0.82 | PAOX (0.61) | POLBALDH1A1PAOXKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | claimed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1416933-B8 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | claimed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | claimed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | claimed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | claimed |
| EP-1416933-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgem, Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| EP-1417190-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgen Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | claimed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | claimed |
| CN-118459477-A | Biotin-optimized FAP targeting compound, preparation method and application thereof, nuclide targeting probe, preparation method and application thereof and pharmaceutical composition | 厦门大学 | 2024-08-09 | — | — | CN | disclosed |
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
| US-4863903-A | RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4719288-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | POLB 2338/4885CA1 4542/4885CA2 3148/4885 |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | POLB 1569/4885CA1 4865/4885CA2 4471/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | POLB 2338/4885CA1 4542/4885CA2 3148/4885 |
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | POLB 1584/4885CA1 4656/4885CA2 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.